The poor clinical response rate of patients with EGFR-mutant NSCLC to anti-PD-1/PD-L1 treatment mechanisms is still unclear but may be associated with the low tumor mutational burden (TMB) of those cancers, leading to weak immunogenicity [224]. This evidence concerns the gene EGFR and cancer.